A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

← catalyst calendar

NCT03423628 · readout in 15 d

Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.

Phase

Phase 1

Status

Active, not recruiting

Study type

Interventional

Design

Na · None · Treatment

Enrollment

159actual

Sites

Countries

Japan, United Kingdom, United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2018-04-02

actual

When the study began enrolling

Primary completion

2026-09-03

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2026-09-03

estimated

The whole study's end, after follow-up

First posted

2018-02-06

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-17

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Recurrent Glioblastoma Multiforme
Primary Glioblastoma Multiforme
Brain Neoplasms, Malignant
Leptomeningeal Disease (LMD)

Interventions

Radiation: Radiation Therapy — also filed as Radiotherapy, Radiation treatment, RT
Drug: AZD1390 — also filed as ATM inhibitor
Radiation: Radiation Therapy — also filed as Radiotherapy, Radiation treatment, RT
Radiation: Radiation Therapy — also filed as Radiotherapy, Radiation treatment, RT
Drug: AZD1390 — also filed as ATM inhibitor
Drug: AZD1390 — also filed as ATM inhibitor

Primary outcomes

what the primary-completion date above is the date OF

Incidence of dose-limiting toxicities (DLTs)

measured From the start of treatment until the end of the DLT period (approximately 6 weeks for Arm A, 3 weeks for Arm B and 10 weeks for Arm C)

Incidence of adverse events (AEs) and serious adverse events (SAEs)

measured From the start of treatment until the end of the study (approximately 9 months after the last patient has started treatment)

Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed